Literature DB >> 1670745

The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers.

R G Englert1, U Barlage.   

Abstract

When doxazosin was given to patients with hypertension not adequately controlled by beta-blockade, blood pressure was normalized in 94% of the 34 patients (blood pressure less than or equal to 140/85 mm Hg). This reduction in blood pressure was obtained with doxazosin in combination with metoprolol or oxprenolol at a mean final daily dose of 1.3 mg or pindolol or atenolol at 2.0 mg/day. Exercise-induced increase in systolic and diastolic blood pressure was also lower with combined beta-blocker and doxazosin therapy than with beta-blocker alone. After 12 weeks of treatment, the combination of doxazosin and beta-blocker significantly reduced total serum cholesterol and triglyceride levels. All side effects were mild and only one patient was withdrawn from therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1670745     DOI: 10.1016/0002-8703(91)90864-e

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

Review 1.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 2.  Neurogenic hypertension: pathophysiology, diagnosis and management.

Authors:  Samuel J Mann
Journal:  Clin Auton Res       Date:  2018-07-04       Impact factor: 4.435

3.  A 6-month large-scale study into the safety of tamsulosin.

Authors:  M C Michel; H U Bressel; M Goepel; H Rübben
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

4.  Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension.

Authors:  Fd Richard Hobbs; Tahir Khan; Barbara Collins
Journal:  Br J Gen Pract       Date:  2005-06       Impact factor: 5.386

Review 5.  Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.

Authors:  B Fulton; A J Wagstaff; E M Sorkin
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

Review 6.  Drug therapy for resistant hypertension: simplifying the approach.

Authors:  Samuel J Mann
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-11-08       Impact factor: 3.738

7.  Combined alpha/beta-blockade: an underused approach to the treatment of resistant hypertension.

Authors:  Samuel J Mann
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-09       Impact factor: 3.738

8.  Doxazosin gastrointestinal therapeutic system: a clinical perspective.

Authors:  Samuel J Mann
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-03       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.